ELAVL1 and cancer: Inhibition of HuR‐ARE interaction can be an attractive strategy in developing new cancer therapeutics.7 Recently, RRMs have been considered for drug design approaches.11, 14 Some compounds have been reported to target RRM1 and RRM2.13, 24, 25 In addition, compounds targeting RRM3 have been reported.14, 24 However, the clinical application of these compounds as anticancer drugs will require a long time.